Table 4 Lipids, statins and anti-platelet therapy
Characteristics | Total (n = 1129) | CKD Stage 3 | CKD Stage 4 | Pvalue |
|---|---|---|---|---|
Total cholesterol (mg/dL; mean ± SD [range]) | 195 ± 42 [30-171] | 193 ± 38 [93-313] | 196 ± 43 [74-396] | 0.27 |
LDL-cholesterol (mg/dL; mean ± SD [range]) | 116 ± 37 [30-271] | 116 ± 38 [39-217] | 116 ± 36 [30-271] | 0.94 |
HDL-cholesterol (mg/dL; mean ± SD [range]) | 50 ± 14 [2-99] | 49 ± 13 [20-99] | 51 ± 14 [23-99] | 0.15 |
Triglycerides (mg/dL; mean ± SD [range]) | 147 ± 89 [40-900] | 151 ± 92 [40-900] | 143 ± 87 [40-860] | 0.14 |
Patients treated with statins for cholesterol control (%) | 54.7 | 56.2 | 53.2 | 0.30 |
Patients with LDL-c < 100 mg/dl (%) | 34.8 | 32.9 | 36.0 | 0.32 |
Patients with LDL-c < 70 mg/dl (%) | 8.3 | 7.6 | 8.8 | 0.52 |
Patients treated with aspirin or other anti-platelet agents (%) | 46.2 | 45.3 | 47.11 | 0.52 |
Patients with serum albumin in normal range (%) | 87.9 | 89.0 | 88.6 | 0.54 |
Serum albumin (g/dL) [range] | 3.9 ± 0.4 [1.7-6] | 3.9 ± 0.4 [1.7-6] | 3.9 ± 0.4 [1.7-6] | 0.79 |